Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line

Resistance to cytotoxic nucleoside analogues is a major problem in cancer treatment. The cellular mechanisms involved in this phenomenon have been studied for several years, and some factors have been identified. Various strategies to overcome resistance have been suggested, but none has yet shown efficacy in vivo. We developed a gemcitabine-resistant cell line (L1210 10K) from the murine leukemic L1210 strain (L1210 wt) by continuous exposure to increasing concentrations of gemcitabine. L1210 10K is highly resistant to gemcitabine (14,833-fold), 1-β-d-arabinofuranosylcytosine (ara-C; 2,100-fold), troxacitabine (>200-fold), and cladribine (160-fold) and slightly resistant to trimidox (7.22-fold), but does not display cross-resistance to fludarabine or nonnucleoside anticancer drugs. Deoxycytidine kinase mRNA was not detected by quantitative real-time reverse transcription-PCR in L1210 10K cells, whereas expression of thymidine kinase 1 and ribonucleotide reductase subunit R2 gene was moderately reduced. L1210 10K cells also demonstrated in vivo resistance to nucleoside analogues: gemcitabine- or ara-C-treated mice carrying L1210 10K had significantly shorter survival than gemcitabine- or ara-C-treated mice carrying L1210 wt (P < 0.05). UA911, a mononucleotide prodrug (pronucleotide) of ara-C was found to significantly sensitize L1210 10K cells in vitro. These results suggest that reduced deoxycytidine kinase expression is a mechanism of resistance to gemcitabine that is relevant in vivo and can be circumvented by a prodrug approach.

[1]  V. Bianchi,et al.  Mammalian 5′-Nucleotidases* , 2003, Journal of Biological Chemistry.

[2]  J. Mackey,et al.  Sensitization of ara‐C‐resistant lymphoma cells by a pronucleotide analogue , 2003, International journal of cancer.

[3]  M. Markman,et al.  Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. , 2003, Gynecologic oncology.

[4]  W. Fowler,et al.  Gemcitabine as a single-agent treatment for ovarian cancer. , 2003, Gynecologic oncology.

[5]  N. James,et al.  The systemic treatment of advanced and metastatic bladder cancer. , 2003, The Lancet. Oncology.

[6]  J. Balzarini,et al.  Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy. , 2003, Biochemical pharmacology.

[7]  C. Dumontet,et al.  Drug resistance to cytotoxic nucleoside analogues. , 2003, Current drug targets.

[8]  H. Hochster.  Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents. , 2003, International journal of radiation oncology, biology, physics.

[9]  J. Mackey,et al.  Deoxycytidine kinase and cN‐II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine , 2003, British journal of haematology.

[10]  V. Heinemann.  Role of Gemcitabine in the Treatment of Advanced and Metastatic Breast Cancer , 2003, Oncology.

[11]  S. Eriksson,et al.  Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. , 2003, Biochemical pharmacology.

[12]  P. Gilman,et al.  Combined Therapy with Topotecan and Gemcitabine in Patients with Inoperable or Metastatic Non-small Cell Lung Cancer , 2003, Cancer investigation.

[13]  G. Peters,et al.  Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. , 2002, International journal of radiation oncology, biology, physics.

[14]  G. Peters,et al.  3'-Azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells. , 2002, Biochemical pharmacology.

[15]  C. Galmarini,et al.  Potential mechanisms of resistance to cytarabine in AML patients. , 2002, Leukemia research.

[16]  Godefridus J Peters,et al.  Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[17]  W. Lam,et al.  Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. , 2002, Cancer research.

[18]  Wing Lam,et al.  Phosphorylation of Pyrimidine Deoxynucleoside Analog Diphosphates , 2002, The Journal of Biological Chemistry.

[19]  H. Doerr,et al.  S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs. , 2002, Antiviral research.

[20]  J. Mackey,et al.  Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. , 2001, Blood.

[21]  K. Nackaerts,et al.  Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  C. Taylor,et al.  Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML , 2001, British Journal of Cancer.

[23]  I. Talianidis,et al.  Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. , 2001, Biochemical pharmacology.

[24]  M. Kaku,et al.  In vitro leukemia cell models of Ara-C resistance. , 2000, Leukemia research.

[25]  G. Keszler,et al.  Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. , 1999, European journal of cancer.

[26]  S. Eriksson,et al.  Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. , 1999, Cancer research.

[27]  G. Peters,et al.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 , 1999, British journal of haematology.

[28]  G. Peters,et al.  Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. , 1999, Biochemical pharmacology.

[29]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[30]  R. D. De Abreu,et al.  Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)-resistant cells. , 1998, Cancer letters.

[31]  G. Peters,et al.  Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. , 1998, Leukemia research.

[32]  Y. Endo,et al.  Development and biochemical characterization of a 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080. , 1998, Cancer letters.

[33]  J. Imbach,et al.  Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidine 5'-monophosphate. , 1995, Journal of medicinal chemistry.

[34]  S. Grant,et al.  Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine. , 1995, Leukemia.

[35]  D. Talbot,et al.  2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Benjamin Rs.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995 .

[37]  D. Ross,et al.  Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. , 1994, Biochemical pharmacology.

[38]  G. Peters,et al.  Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. , 1994, Cancer research.

[39]  B. Mitchell,et al.  Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. , 1994, Leukemia.

[40]  G. Peters,et al.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.

[41]  R. Willemze,et al.  Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. , 1993, Leukemia.

[42]  J. Laliberté,et al.  Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. , 1993, Biochemical pharmacology.

[43]  Y Z Xu,et al.  Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. , 1992, Cancer research.

[44]  L. Hertel,et al.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis. , 1991, Cancer research.

[45]  Y Z Xu,et al.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.

[46]  D. Ives,et al.  Human deoxycytidine kinase: kinetic mechanism and end product regulation. , 1989, Biochemistry.

[47]  B. Mitchell,et al.  Kinetic properties and inhibition of human T lymphoblast deoxycytidine kinase. , 1989, The Journal of biological chemistry.

[48]  T. Chan.  Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux. , 1989, Cancer research.

[49]  V. Avramis,et al.  Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1. , 1987, Cancer research.

[50]  T. Spasokoukotskaja,et al.  Modulation of human deoxycytidine kinase activity as a response to cellular stress induced by NaF. , 2001, Acta biochimica Polonica.

[51]  J. Mackey,et al.  Nucleoside transport and its significance for anticancer drug resistance. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[52]  K. Kishi,et al.  Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. , 1998, Leukemia & lymphoma.

[53]  M. Yamaguchi,et al.  Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-β-d-arabinofuranosyl-2-fluoroadenine , 1998, Journal of Cancer Research and Clinical Oncology.

[54]  V. Heinemann,et al.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. , 1995, Seminars in oncology.

[55]  K. Kishi,et al.  Low expression of the deoxycytidine kinase (dCK) gene in a 1-beta-D-arabinofuranosylcytosine-resistant human leukemic cell line KY-Ra. , 1994, Leukemia & lymphoma.